Ivacaftor is the first U.S. Food and Drug Administration (FDA)-approved CFTR protein used to treat CF patients who have a G551D mutation, which affects expression of the CFTR gene and changes the frequency of ion channel opening [6,7]. This evidence concerns the gene CFTR and cystic fibrosis.